Kidney function and olpasiran: a safety check

NCT ID NCT05489614

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study looked at how the drug olpasiran moves through the body in people with normal kidneys and those with kidney problems. 33 adults received one dose to measure drug levels and safety. The goal was to gather information, not to treat any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Advanced Pharma CR, LLC

Miami, Florida, 33147-4040, United States
CRSCA HC LLC, dba Creekside Post Acute

Yucaipa, California, 92399, United States
Clinical Pharmacology Of Miami, LLC

Miami, Florida, 33014, United States
Inland Empire Clinical Trials, LLC

Rialto, California, 92377-4697, United States
Nucleus Network - Minneapolis

Saint Paul, Minnesota, 55114, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States

Conditions

Explore the condition pages connected to this study.

RENAL IMPAIRMENT